STRATA Skin Sciences, Inc. (SSKN): Nasdaq/NYSE listing notice — STRATA Skin Sciences receives Nasdaq deficiency notice for bid price below $1.00

STRATA Skin Sciences, Inc.

Received Nasdaq notice on Oct 26, 2022 for non-compliance with minimum bid price rule (closing bid below $1.00 for 30 consecutive business days).
Initial compliance period of 180 calendar days expires April 24, 2023.
To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
Failure to achieve compliance by deadline may lead to delisting; extension or appeal possible.
Company evaluating available options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 26, 2022, STRATA Skin Sciences, Inc. (the "Company") received written notification (the "Notice") from The NASDAQ Stock Market ("NASDAQ") that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until April 24, 2023, to regain compliance with the listing rules. The C

View on SEC.gov

Browse all listing & compliance notices →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001051514-22-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.